Latest:
Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC
Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non-small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Robert Coleman, MD
Latest:
Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Robert D. Orzechowski, MBA
Latest:
Implementing Quality Standards and Personalized Approaches into Oncology
Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.
Robert Dreicer, MD, MS, MACP, FASCO, University of Virginia Cancer Center
Latest:
Dr Dreicer on Managing Biochemical Failure Post-Radical Prostatectomy in Prostate Cancer
Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.
Robert E. Coleman, MBBS, MD, FRCP, FRCPE
Latest:
Dr. Coleman on Findings From the AZURE Trial for Breast Cancer Treatment
Robert E. Coleman, MBBS, MD, FRCP, FRCPE, professor of Medical Oncology and head of the Academic Unit of Clinical Oncology at the University of Sheffield, discusses the safety findings from the 10-year follow-up of the adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer, which was studied in the AZURE trial.
Robert E. Merritt, MD, FACS
Latest:
Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLC
Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.
Robert Ferris, MD, PhD
Latest:
Dr. Ferris on the CheckMate-041 Trial For Head and Neck Cancer
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the significance of the CheckMate-041 trial for patients with head and neck cancer.
Robert Figlin, MD
Latest:
Dr. Figlin on Advice for Oncologists Treating RCC
Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.